{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T03:53:54Z","timestamp":1795146834864,"version":"4.10.3"},"reference-count":206,"publisher":"Oxford University Press (OUP)","issue":"47","license":[{"start":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:00:00Z","timestamp":1630540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"The European Atherosclerosis Society Consensus Panel","id":[{"id":"https:\/\/ror.org\/03zjxnp55","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Recent advances in human genetics, together with a large body of epidemiologic, preclinical, and clinical trial results, provide strong support for a causal association between triglycerides (TG), TG-rich lipoproteins (TRL), and TRL remnants, and increased risk of myocardial infarction, ischaemic stroke, and aortic valve stenosis. These data also indicate that TRL and their remnants may contribute significantly to residual cardiovascular risk in patients on optimized low-density lipoprotein (LDL)-lowering therapy. This statement critically appraises current understanding of the structure, function, and metabolism of TRL, and their pathophysiological role in atherosclerotic cardiovascular disease (ASCVD). Key points are (i) a working definition of normo- and hypertriglyceridaemic states and their relation to risk of ASCVD, (ii) a conceptual framework for the generation of remnants due to dysregulation of TRL production, lipolysis, and remodelling, as well as clearance of remnant lipoproteins from the circulation, (iii) the pleiotropic proatherogenic actions of TRL and remnants at the arterial wall, (iv) challenges in defining, quantitating, and assessing the atherogenic properties of remnant particles, and (v) exploration of the relative atherogenicity of TRL and remnants compared to LDL. Assessment of these issues provides a foundation for evaluating approaches to effectively reduce levels of TRL and remnants by targeting either production, lipolysis, or hepatic clearance, or a combination of these mechanisms. This consensus statement updates current understanding in an integrated manner, thereby providing a platform for new therapeutic paradigms targeting TRL and their remnants, with the aim of reducing the risk of ASCVD.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehab551","type":"journal-article","created":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T15:19:50Z","timestamp":1627658390000},"page":"4791-4806","source":"Crossref","is-referenced-by-count":1000,"title":["Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies\u2014a consensus statement from the European Atherosclerosis Society"],"prefix":"10.1093","volume":"42","author":[{"given":"Henry N","family":"Ginsberg","sequence":"first","affiliation":[{"name":"Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University , 630 West 168th Street, PH-10-305 , New York, NY 10032, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris J","family":"Packard","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular and Medical Sciences, University of Glasgow , 126 University Place, Glasgow G12 8TA, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M John","family":"Chapman","sequence":"additional","affiliation":[{"name":"Sorbonne University Endocrinology-Metabolism Division, Piti\u00e9-Salpetriere University Hospital, and National Institute for Health and Medical Research (INSERM) , 47 H\u00f4pital boulevard, Paris 75013, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Bor\u00e9n","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Medicine, University of Gothenburg and Sahlgrenska University Hospital , Bl\u00e5 Str\u00e5ket 5, Gothenburg 413 45, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8517-0241","authenticated-orcid":false,"given":"Carlos A","family":"Aguilar-Salinas","sequence":"additional","affiliation":[{"name":"Unidad de Investigaci\u00f3n en Enfermedades Metab\u00f3licas and Departamento de Endocrinolog\u00eda y Metabolismo, Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir \u00a0 , Vasco de Quiroga 15, Belisario Dom\u00ednguez Secc 16, Tlalpan, Mexico City 14080, Mexico"},{"name":"\u00e1n \u00a0 , Vasco de Quiroga 15, Belisario Dom\u00ednguez Secc 16, Tlalpan, Mexico City 14080, Mexico"},{"name":"Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud , Ave. Morones Prieto , Monterrey, Nuevo Le\u00f3n 3000, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Averna","sequence":"additional","affiliation":[{"name":"Department of Health Promotion Sciences Maternal and Infantile Care, Internal Medicine and Medical Specialities, University of Palermo , Marina Square, 61, Palermo 90133, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A","family":"Ference","sequence":"additional","affiliation":[{"name":"Centre for Naturally Randomized Trials, University of Cambridge , Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5185-3666","authenticated-orcid":false,"given":"Daniel","family":"Gaudet","sequence":"additional","affiliation":[{"name":"Clinical Lipidology and Rare Lipid Disorders Unit, Community Genomic Medicine Center, Department of Medicine, Universit\u00e9 de Montr\u00e9al, ECOGENE, Clinical and Translational Research Center, and Lipid Clinic, Chicoutimi \u00a0 , 305 Rue St Vallier, Chicoutimi, Qu\u00e9bec G7H 5H6, Canada"},{"name":"Hospital \u00a0 , 305 Rue St Vallier, Chicoutimi, Qu\u00e9bec G7H 5H6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2861-5325","authenticated-orcid":false,"given":"Robert A","family":"Hegele","sequence":"additional","affiliation":[{"name":"Department of Medicine and Robarts Research Institute, Schulich School of Medicine and Dentistry, Western Universi \u00a0 , 1151 Richmond Street, London, Ontario N6A 3K7, Canada"},{"name":"ty \u00a0 , 1151 Richmond Street, London, Ontario N6A 3K7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander","family":"Kersten","sequence":"additional","affiliation":[{"name":"Division of Human Nutrition and Health, Wageningen University , Wageningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary F","family":"Lewis","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Medicine, Banting & Best Diabetes Centre, University of Toronto , Eaton Building, Room 12E248, 200 Elizabeth St, Toronto, Ontario M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1053-9478","authenticated-orcid":false,"given":"Alice H","family":"Lichtenstein","sequence":"additional","affiliation":[{"name":"Cardiovascular Nutrition, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University , 711 Washington St Ste 9, Boston, MA 02111, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8344-7814","authenticated-orcid":false,"given":"Philippe","family":"Moulin","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, GHE, Hospices Civils de Lyon, CarMeN Laboratory, Inserm UMR 1060, CENS-ELI B, Univ-Lyon1 , Lyon 69003, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1954-7220","authenticated-orcid":false,"given":"B\u00f8rge G","family":"Nordestgaard","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University \u00a0 , Herlev Ringvej 75, Herlev 2730, Denmark"},{"name":"Hospital \u00a0 , Herlev Ringvej 75, Herlev 2730, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen , Blegdamsvej 3B, Copenhagen DK-2200, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan T","family":"Remaley","sequence":"additional","affiliation":[{"name":"Lipoprotein Metabolism Section, Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of \u00a0 , 31 Center Dr Ste 10-7C114, Bethesda, MD 20892, USA"},{"name":"Health \u00a0 , 31 Center Dr Ste 10-7C114, Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3784-1503","authenticated-orcid":false,"given":"Bart","family":"Staels","sequence":"additional","affiliation":[{"name":"Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID , Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9555-6260","authenticated-orcid":false,"given":"Erik S G","family":"Stroes","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Academic Medical \u00a0 , 1541 Kings Hwy, Amsterdam 71103, The Netherlands"},{"name":"Center \u00a0 , 1541 Kings Hwy, Amsterdam 71103, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marja-Riitta","family":"Taskinen","sequence":"additional","affiliation":[{"name":"Research Programs Unit, Clinical and Molecular Metabolism, University of Helsinki , Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6441-3339","authenticated-orcid":false,"given":"Lale S","family":"Tokg\u00f6zo\u011flu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hacettepe University Faculty of Medicine , 06100 S\u0131hhiye, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Tybjaerg-Hansen","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Blegdamsvej 9, Rigshospitalet , Copenhagen 2100, Denmark"},{"name":"Copenhagen General Population Study, Herlev and Gentofte Hospital , Herlev, Denmark"},{"name":"Copenhagen City Heart Study, Frederiksberg \u00a0 , Nordre Fasanvej, Frederiksberg 57 2000, Denmark"},{"name":"Hospital \u00a0 , Nordre Fasanvej, Frederiksberg 57 2000, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of \u00a0 , Blegdamsvej, Copenhagen 3B 2200, Denmark"},{"name":"Copenhagen \u00a0 , Blegdamsvej, Copenhagen 3B 2200, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane K","family":"Stock","sequence":"additional","affiliation":[{"name":"European Atherosclerosis Society , M\u00e4ssans Gata 10 , Gothenburg SE-412 51, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberico L","family":"Catapano","sequence":"additional","affiliation":[{"name":"Department of Pharmacological and Biomolecular Sciences, Universit\u00e0 degli Studi di Milano and IRCCS MultiMedica , Via Festa del Perdono 7, Milan 20122, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,9,2]]},"reference":[{"key":"2022102613584224300_ehab551-B1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1161\/01.ATV.11.1.2","article-title":"Plasma triglyceride and coronary heart disease","volume":"11","author":"Austin","year":"1991","journal-title":"Arterioscler Thromb"},{"key":"2022102613584224300_ehab551-B2","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/eurheartj\/ehr112","article-title":"Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management","volume":"32","author":"Chapman","year":"2011","journal-title":"Eur Heart J"},{"key":"2022102613584224300_ehab551-B3","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/joim.12877","article-title":"Investigation of human apoB48 metabolism using a new, integrated non-steady-state model of apoB48 and apoB100 kinetics","volume":"285","author":"Bj\u00f6rnson","year":"2019","journal-title":"J Intern Med"},{"key":"2022102613584224300_ehab551-B4","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1161\/CIR.0b013e3182160726","article-title":"Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association","volume":"123","author":"Miller","year":"2011","journal-title":"Circulation"},{"key":"2022102613584224300_ehab551-B5","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S0022-2275(20)32142-8","article-title":"Characterization of remnant-like particles isolated by immunoaffinity gel from the plasma of type III and type IV hyperlipoproteinemic patients","volume":"40","author":"Marcoux","year":"1999","journal-title":"J Lipid Res"},{"key":"2022102613584224300_ehab551-B6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0076-6879(86)28061-1","article-title":"Introduction to the plasma lipoproteins","volume":"128","author":"Gotto","year":"1986","journal-title":"Methods Enzymol"},{"key":"2022102613584224300_ehab551-B7","first-page":"451","volume-title":"Handbook of Lipoprotein Testing","author":"Havel","year":"1997"},{"key":"2022102613584224300_ehab551-B8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1161\/01.ATV.6.1.79","article-title":"Presence of multiple subpopulations of lipoproteins of intermediate density in normal subjects","volume":"6","author":"Musliner","year":"1986","journal-title":"Arteriosclerosis"},{"key":"2022102613584224300_ehab551-B9","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1016\/S0022-2275(20)37557-X","article-title":"Differences in LDL subspecies involve alterations in lipid composition and conformational changes in apolipoprotein B","volume":"37","author":"McNamara","year":"1996","journal-title":"J Lipid Res"},{"key":"2022102613584224300_ehab551-B10","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jacl.2012.06.005","article-title":"The interaction of familial and secondary causes of hypertriglyceridemia: role in pancreatitis","volume":"6","author":"Brunzell","year":"2012","journal-title":"J Clin Lipidol"},{"key":"2022102613584224300_ehab551-B11","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1001\/jamainternmed.2016.6875","article-title":"Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis","volume":"176","author":"Pedersen","year":"2016","journal-title":"JAMA Intern Med"},{"key":"2022102613584224300_ehab551-B12","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1373\/clinchem.2018.294926","article-title":"Low-grade inflammation in the association between mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis: a study of more than 115000 individuals from the general population","volume":"65","author":"Hansen","year":"2019","journal-title":"Clin Chem"},{"key":"2022102613584224300_ehab551-B13","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S2213-8587(13)70191-8","article-title":"The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management","volume":"2","author":"Hegele","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022102613584224300_ehab551-B14","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1161\/01.CIR.82.2.495","article-title":"Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk","volume":"82","author":"Austin","year":"1990","journal-title":"Circulation"},{"key":"2022102613584224300_ehab551-B15","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/S0735-1097(98)00083-7","article-title":"Normal triglyceride levels and coronary artery disease events: the Baltimore Coronary Observational Long-Term Study","volume":"31","author":"Miller","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"2022102613584224300_ehab551-B16","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/eurheartj\/ehz767","article-title":"Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies","volume":"41","author":"Lawler","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102613584224300_ehab551-B17","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","article-title":"Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology","volume":"118","author":"Nordestgaard","year":"2016","journal-title":"Circ Res"},{"key":"2022102613584224300_ehab551-B18","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S2213-8587(19)30264-5","article-title":"Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement","volume":"8","author":"Hegele","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022102613584224300_ehab551-B19","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2009.1619","article-title":"Major lipids, apolipoproteins, and risk of vascular disease","volume":"302","author":"Di Angelantonio","year":"2009","journal-title":"JAMA"},{"key":"2022102613584224300_ehab551-B20","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102613584224300_ehab551-B21","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS Guidelines for the Management of Dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"2022102613584224300_ehab551-B22","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur Heart J"},{"key":"2022102613584224300_ehab551-B23","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1373\/clinchem.2015.253757","article-title":"Increased remnant cholesterol explains part of residual risk of all-cause mortality in 5414 patients with ischemic heart disease","volume":"62","author":"Jepsen","year":"2016","journal-title":"Clin Chem"},{"key":"2022102613584224300_ehab551-B24","doi-asserted-by":"crossref","first-page":"7B","DOI":"10.1016\/S0002-9149(98)00031-9","article-title":"Hypertriglyceridemia as a cardiovascular risk factor","volume":"81","author":"Austin","year":"1998","journal-title":"Am J Cardiol"},{"key":"2022102613584224300_ehab551-B25","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"Lancet"},{"key":"2022102613584224300_ehab551-B26","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1001\/jama.2018.20045","article-title":"Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease","volume":"321","author":"Ference","year":"2019","journal-title":"JAMA"},{"key":"2022102613584224300_ehab551-B27","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/ana.25432","article-title":"Remnant cholesterol and risk of ischemic stroke in 112,512 individuals from the general population","volume":"85","author":"Varbo","year":"2019","journal-title":"Ann Neurol"},{"key":"2022102613584224300_ehab551-B28","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1093\/eurheartj\/ehaa172","article-title":"Triglycerides and remnant cholesterol associated with risk of aortic valve stenosis: Mendelian randomization in the Copenhagen General Population Study","volume":"41","author":"Kaltoft","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102613584224300_ehab551-B29","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature13917","article-title":"Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction","volume":"518","author":"Do","year":"2015","journal-title":"Nature"},{"key":"2022102613584224300_ehab551-B30","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-function mutations in APOC3 and risk of ischemic vascular disease","volume":"371","author":"J\u00f8rgensen","year":"2014","journal-title":"N Engl J Med"},{"key":"2022102613584224300_ehab551-B31","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jama.2017.0972","article-title":"Association of rare and common variation in the lipoprotein lipase gene with coronary artery disease","volume":"317","author":"Khera","year":"2017","journal-title":"JAMA"},{"key":"2022102613584224300_ehab551-B32","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.jacc.2017.02.030","article-title":"ANGPTL3 deficiency and protection against coronary artery disease","volume":"69","author":"Stitziel","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2022102613584224300_ehab551-B33","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJMoa1510926","article-title":"Inactivating variants in ANGPTL4 and risk of coronary artery disease","volume":"374","author":"Dewey","year":"2016","journal-title":"N Engl J Med"},{"key":"2022102613584224300_ehab551-B34","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJMoa1507652","article-title":"Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease","volume":"374","author":"Stitziel","year":"2016","journal-title":"N Engl J Med"},{"key":"2022102613584224300_ehab551-B35","doi-asserted-by":"crossref","first-page":"e1009501","DOI":"10.1371\/journal.pgen.1009501","article-title":"ANGPTL8 protein-truncating variant associated with lower serum triglycerides and risk of coronary disease","volume":"17","author":"Helkkula","year":"2021","journal-title":"PLoS Genet"},{"key":"2022102613584224300_ehab551-B36","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2337\/dbi19-0007","article-title":"Remnants of the triglyceride-rich lipoproteins, diabetes, and cardiovascular disease","volume":"69","author":"Chait","year":"2020","journal-title":"Diabetes"},{"key":"2022102613584224300_ehab551-B37","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1161\/CIRCULATIONAHA.117.032318","article-title":"Triglyceride-rich lipoprotein cholesterol and risk of cardiovascular events among patients receiving statin therapy in the TNT Trial","volume":"138","author":"Vallejo-Vaz","year":"2018","journal-title":"Circulation"},{"key":"2022102613584224300_ehab551-B38","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1016\/j.jacc.2021.04.059","article-title":"Triglycerides and residual atherosclerotic risk","volume":"77","author":"Raposeiras-Roubin","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2022102613584224300_ehab551-B39","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1161\/CIRCULATIONAHA.119.041998","article-title":"Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes: a systematic review and meta-regression analysis of randomized controlled trials","volume":"140","author":"Marston","year":"2019","journal-title":"Circulation"},{"key":"2022102613584224300_ehab551-B40","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1016\/j.jacc.2015.03.544","article-title":"Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins","volume":"65","author":"Schwartz","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2022102613584224300_ehab551-B41","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1161\/01.CIR.102.16.1893","article-title":"Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project","volume":"102","author":"Sacks","year":"2000","journal-title":"Circulation"},{"key":"2022102613584224300_ehab551-B42","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jacc.2007.10.038","article-title":"Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial","volume":"51","author":"Miller","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2022102613584224300_ehab551-B43","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","article-title":"Clinical review on triglycerides","volume":"41","author":"Laufs","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102613584224300_ehab551-B44","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3389\/fendo.2020.00252","article-title":"Causes and consequences of hypertriglyceridemia","volume":"11","author":"Packard","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2022102613584224300_ehab551-B45","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.tem.2020.11.005","article-title":"Lipoprotein lipase and its regulators: an unfolding story","volume":"32","author":"Cheng","year":"2021","journal-title":"Trends Endocrinol Metab"},{"key":"2022102613584224300_ehab551-B46","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3389\/fendo.2020.00616","article-title":"Hypertriglyceridemia\u2014causes, significance, and approaches to therapy","volume":"11","author":"Santos-Baez","year":"2020","journal-title":"Front Endocrinol"},{"key":"2022102613584224300_ehab551-B47","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1146\/annurev-nutr-071714-034338","article-title":"New insights into the regulation of chylomicron production","volume":"35","author":"Dash","year":"2015","journal-title":"Annu Rev Nutr"},{"key":"2022102613584224300_ehab551-B48","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41575-019-0250-7","article-title":"Regulation of intestinal lipid metabolism: current concepts and relevance to disease","volume":"17","author":"Ko","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2022102613584224300_ehab551-B49","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.tem.2017.12.001","article-title":"Recent advances in triacylglycerol mobilization by the gut","volume":"29","author":"Xiao","year":"2018","journal-title":"Trends Endocrinol Metab"},{"key":"2022102613584224300_ehab551-B50","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/MOL.0000000000000495","article-title":"Regulation of intestinal lipid and lipoprotein metabolism by the proglucagon-derived peptides glucagon like peptide 1 and glucagon like peptide 2","volume":"29","author":"Mulvihill","year":"2018","journal-title":"Curr Opin Lipidol"},{"key":"2022102613584224300_ehab551-B51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MOL.0000000000000254","article-title":"Central nervous system regulation of intestinal lipid and lipoprotein metabolism","volume":"27","author":"Farr","year":"2016","journal-title":"Curr Opin Lipidol"},{"key":"2022102613584224300_ehab551-B52","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1161\/ATVBAHA.119.313011","article-title":"Glucose and GLP-2 (Glucagon-Like Peptide-2) mobilize intestinal triglyceride by distinct mechanisms","volume":"39","author":"Stahel","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022102613584224300_ehab551-B53","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1161\/ATVBAHA.107.160192","article-title":"Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome","volume":"28","author":"Adiels","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022102613584224300_ehab551-B54","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1210\/jc.2016-1500","article-title":"VLDL triglyceride kinetics in lean, overweight, and obese men and women","volume":"101","author":"Mittendorfer","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2022102613584224300_ehab551-B55","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nrm4074","article-title":"Transcriptional regulation of hepatic lipogenesis","volume":"16","author":"Wang","year":"2015","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2022102613584224300_ehab551-B56","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/MOL.0000000000000676","article-title":"Regulation of lipoprotein lipase-mediated lipolysis of triglycerides","volume":"31","author":"Basu","year":"2020","journal-title":"Curr Opin Lipidol"},{"key":"2022102613584224300_ehab551-B57","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3389\/fendo.2020.00455","article-title":"Genetics of hypertriglyceridemia","volume":"11","author":"Dron","year":"2020","journal-title":"Front Endocrinol"},{"key":"2022102613584224300_ehab551-B58","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1161\/ATVBAHA.110.221846","article-title":"ApoCIII, 42 years old and even more interesting","volume":"31","author":"Ginsberg","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022102613584224300_ehab551-B59","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1172\/JCI112713","article-title":"Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI: evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo","volume":"78","author":"Ginsberg","year":"1986","journal-title":"J Clin Invest"},{"key":"2022102613584224300_ehab551-B60","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1126\/science.1161524","article-title":"A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection","volume":"322","author":"Pollin","year":"2008","journal-title":"Science"},{"key":"2022102613584224300_ehab551-B61","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1161\/ATVBAHA.111.224808","article-title":"Dual metabolic defects are required to produce hypertriglyceridemia in obese subjects","volume":"31","author":"Taskinen","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022102613584224300_ehab551-B62","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1111\/dom.13744","article-title":"Role of apolipoprotein C-III overproduction in diabetic dyslipidaemia","volume":"21","author":"Adiels","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"2022102613584224300_ehab551-B63","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1172\/JCI200523219","article-title":"Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus","volume":"115","author":"Nagashima","year":"2005","journal-title":"J Clin Invest"},{"key":"2022102613584224300_ehab551-B64","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1194\/jlr.P066183","article-title":"Effects of angiopoietin-like protein 3 deficiency on postprandial lipid and lipoprotein metabolism","volume":"57","author":"Minicocci","year":"2016","journal-title":"J Lipid Res"},{"key":"2022102613584224300_ehab551-B65","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease","volume":"377","author":"Dewey","year":"2017","journal-title":"N Engl J Med"},{"key":"2022102613584224300_ehab551-B66","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1194\/jlr.P119000543","article-title":"LDL subclass lipidomics in atherogenic dyslipidemia: effect of statin therapy on bioactive lipids and dense LDL","volume":"61","author":"Chapman","year":"2020","journal-title":"J Lipid Res"},{"key":"2022102613584224300_ehab551-B67","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1161\/01.ATV.19.10.2474","article-title":"Detection, quantification, and characterization of potentially atherogenic triglyceride-rich remnant lipoproteins","volume":"19","author":"Cohn","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022102613584224300_ehab551-B68","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1161\/01.CIR.0000125278.58527.F3","article-title":"Elevated remnant-like particle cholesterol concentration: a characteristic feature of the atherogenic lipoprotein phenotype","volume":"109","author":"Twickler","year":"2004","journal-title":"Circulation"},{"key":"2022102613584224300_ehab551-B69","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1172\/JCI1240","article-title":"Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants","volume":"101","author":"Rohlmann","year":"1998","journal-title":"J Clin Invest"},{"key":"2022102613584224300_ehab551-B70","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1161\/ATVBAHA.113.301637","article-title":"Hepatic remnant lipoprotein clearance by heparan sulfate proteoglycans and low-density lipoprotein receptors depend on dietary conditions in mice","volume":"33","author":"Foley","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022102613584224300_ehab551-B71","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1172\/JCI30889","article-title":"Atherogenic remnant lipoproteins: role for proteoglycans in trapping, transferring, and internalizing","volume":"117","author":"Mahley","year":"2007","journal-title":"J Clin Invest"},{"key":"2022102613584224300_ehab551-B72","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1373\/clinchem.2014.234146","article-title":"Extreme nonfasting remnant cholesterol vs. extreme LDL cholesterol as contributors to cardiovascular disease and all-cause mortality in 90000 individuals from the general population","volume":"61","author":"Varbo","year":"2015","journal-title":"Clin Chem"},{"key":"2022102613584224300_ehab551-B73","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11886-016-0745-6","article-title":"Triglyceride-rich lipoproteins and remnants: targets for therapy?","volume":"18","author":"Dallinga-Thie","year":"2016","journal-title":"Curr Cardiol Rep"},{"key":"2022102613584224300_ehab551-B74","doi-asserted-by":"crossref","first-page":"8303","DOI":"10.1016\/S0021-9258(19)70647-4","article-title":"Regulation of the hepatic uptake of triglyceride-rich lipoproteins in the rat: opposing effects of homologeous apolipoprotein E and individual C apoproteins","volume":"255","author":"Windler","year":"1980","journal-title":"J Biol Chem"},{"key":"2022102613584224300_ehab551-B75","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1194\/jlr.M093740","article-title":"ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance","volume":"60","author":"Ramms","year":"2019","journal-title":"J Lipid Res"},{"key":"2022102613584224300_ehab551-B76","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1194\/jlr.RA120000888","article-title":"Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance","volume":"61","author":"Adam","year":"2020","journal-title":"J Lipid Res"},{"key":"2022102613584224300_ehab551-B77","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1172\/JCI105290","article-title":"Kinetics of triglyceride turnover of very low density lipoproteins of human plasma","volume":"44","author":"Reaven","year":"1965","journal-title":"J Clin Invest"},{"key":"2022102613584224300_ehab551-B78","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1093\/eurheartj\/ehw152","article-title":"Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points\u2014a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine","volume":"37","author":"Nordestgaard","year":"2016","journal-title":"Eur Heart J"},{"key":"2022102613584224300_ehab551-B79","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1373\/clinchem.2018.287037","article-title":"Quantifying atherogenic lipoproteins: current and future challenges in the era of personalized medicine and very low concentrations of LDL cholesterol. A Consensus Statement from EAS and EFLM","volume":"64","author":"Langlois","year":"2018","journal-title":"Clin Chem"},{"key":"2022102613584224300_ehab551-B80","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0021-9150(00)00554-2","article-title":"Diurnal triglyceride profiles: a novel approach to study triglyceride changes","volume":"155","author":"Castro Cabezas","year":"2001","journal-title":"Atherosclerosis"},{"key":"2022102613584224300_ehab551-B81","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1194\/jlr.M074062","article-title":"Weekday variation in triglyceride concentrations in 1.8 million blood samples","volume":"58","author":"Jaskolowski","year":"2017","journal-title":"J Lipid Res"},{"key":"2022102613584224300_ehab551-B82","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1161\/CIRCULATIONAHA.108.804146","article-title":"Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction","volume":"118","author":"Langsted","year":"2008","journal-title":"Circulation"},{"key":"2022102613584224300_ehab551-B83","doi-asserted-by":"crossref","first-page":"498","DOI":"10.2174\/1570161117666190507110519","article-title":"Postprandial hypertriglyceridaemia revisited in the era of non-fasting lipid profile testing: a 2019 Expert Panel Statement, Main Text","volume":"17","author":"Kolovou","year":"2019","journal-title":"Curr Vasc Pharmacol"},{"key":"2022102613584224300_ehab551-B84","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.298.3.309","article-title":"Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women","volume":"298","author":"Bansal","year":"2007","journal-title":"JAMA"},{"key":"2022102613584224300_ehab551-B85","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1001\/jama.2008.621","article-title":"Nonfasting triglycerides and risk of ischemic stroke in the general population","volume":"300","author":"Freiberg","year":"2008","journal-title":"JAMA"},{"key":"2022102613584224300_ehab551-B86","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.cca.2014.01.015","article-title":"Postprandial hypertriglyceridemia as a coronary risk factor","volume":"431","author":"Bor\u00e9n","year":"2014","journal-title":"Clin Chim Acta"},{"key":"2022102613584224300_ehab551-B87","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1016\/S0022-2275(20)35345-1","article-title":"Contribution of apoB-48 and apoB-100 triglyceride-rich lipoproteins (TRL) to postprandial increases in the plasma concentration of TRL triglycerides and retinyl esters","volume":"34","author":"Cohn","year":"1993","journal-title":"J Lipid Res"},{"key":"2022102613584224300_ehab551-B88","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1161\/01.ATV.15.2.199","article-title":"Quantification of postprandial triglyceride-rich lipoproteins in healthy men by retinyl ester labeling and simultaneous measurement of apolipoproteins B-48 and B-100","volume":"15","author":"Karpe","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022102613584224300_ehab551-B89","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.bbalip.2012.01.006","article-title":"Postprandial metabolism of meal triglyceride in humans","volume":"1821","author":"Lambert","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"2022102613584224300_ehab551-B90","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.bbalip.2009.01.001","article-title":"Oro-sensory perception of dietary lipids: new insights into the fat taste transduction","volume":"1791","author":"Khan","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"2022102613584224300_ehab551-B91","doi-asserted-by":"crossref","first-page":"G365","DOI":"10.1152\/ajpgi.90591.2008","article-title":"Brief oral stimulation, but especially oral fat exposure, elevates serum triglycerides in humans","volume":"296","author":"Mattes","year":"2009","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2022102613584224300_ehab551-B92","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/joim.13017","article-title":"Apolipoprotein B48 metabolism in chylomicrons and very low-density lipoproteins and its role in triglyceride transport in normo- and hypertriglyceridemic human subjects","volume":"288","author":"Bjornson","year":"2020","journal-title":"J Intern Med"},{"key":"2022102613584224300_ehab551-B93","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"41","author":"Bor\u00e9n","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102613584224300_ehab551-B94","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1161\/01.RES.0000170946.56981.5c","article-title":"New insights into the regulation of HDL metabolism and reverse cholesterol transport","volume":"96","author":"Lewis","year":"2005","journal-title":"Circ Res"},{"key":"2022102613584224300_ehab551-B95","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/eurheartj\/ehp399","article-title":"Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors","volume":"31","author":"Chapman","year":"2010","journal-title":"Eur Heart J"},{"key":"2022102613584224300_ehab551-B96","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1042\/CS20190873","article-title":"Altered HDL metabolism in metabolic disorders: insights into the therapeutic potential of HDL","volume":"133","author":"Hui","year":"2019","journal-title":"Clin Sci"},{"key":"2022102613584224300_ehab551-B97","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1172\/JCI116384","article-title":"Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol","volume":"91","author":"Horowitz","year":"1993","journal-title":"J Clin Invest"},{"key":"2022102613584224300_ehab551-B98","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/MOL.0b013e328352dd1a","article-title":"Hepatic ABC transporters and triglyceride metabolism","volume":"23","author":"Parks","year":"2012","journal-title":"Curr Opin Lipidol"},{"key":"2022102613584224300_ehab551-B99","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.bbalip.2013.07.009","article-title":"Dyslipidemia, but not hyperglycemia and insulin resistance, is associated with marked alterations in the HDL lipidome in type 2 diabetic subjects in the DIWA cohort: impact on small HDL particles","volume":"1831","author":"St\u00e5hlman","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"2022102613584224300_ehab551-B100","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1161\/ATVBAHA.108.179317","article-title":"Proteomics of apolipoproteins and associated proteins from plasma high-density lipoproteins","volume":"30","author":"Davidsson","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022102613584224300_ehab551-B101","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11892-008-0010-5","article-title":"Why is HDL functionally deficient in type 2 diabetes?","volume":"8","author":"Kontush","year":"2008","journal-title":"Curr Diab Rep"},{"key":"2022102613584224300_ehab551-B102","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrcardio.2015.124","article-title":"Dysfunctional HDL and atherosclerotic cardiovascular disease","volume":"13","author":"Rosenson","year":"2016","journal-title":"Nat Rev Cardiol"},{"key":"2022102613584224300_ehab551-B103","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0092-8674(00)80213-5","article-title":"The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor","volume":"89","author":"Brown","year":"1997","journal-title":"Cell"},{"key":"2022102613584224300_ehab551-B104","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"2022102613584224300_ehab551-B105","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.cca.2017.12.039","article-title":"Atherogenic postprandial remnant lipoproteins; VLDL remnants as a causal factor in atherosclerosis","volume":"478","author":"Nakajima","year":"2018","journal-title":"Clin Chim Acta"},{"key":"2022102613584224300_ehab551-B106","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.acvd.2020.11.006","article-title":"Triglycerides and risk of atherosclerotic cardiovascular disease: an update","volume":"114","author":"Farnier","year":"2021","journal-title":"Arch Cardiovasc Dis"},{"key":"2022102613584224300_ehab551-B107","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/clinchem\/hvaa296","article-title":"Triglyceride-rich lipoprotein remnants and cardiovascular disease","volume":"67","author":"Duran","year":"2021","journal-title":"Clin Chem"},{"key":"2022102613584224300_ehab551-B108","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1210\/er.2018-00184","article-title":"The forgotten lipids: triglycerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk","volume":"40","author":"Sandesara","year":"2019","journal-title":"Endocr Rev"},{"key":"2022102613584224300_ehab551-B109","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0022-2275(20)32522-0","article-title":"Differences in apolipoprotein and lipid composition between human chylomicron remnants and very low density lipoproteins isolated from fasting and postprandial plasma","volume":"39","author":"Bj\u00f6rkegren","year":"1998","journal-title":"J Lipid Res"},{"key":"2022102613584224300_ehab551-B110","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.cca.2012.02.026","article-title":"The characteristics of remnant lipoproteins in the fasting and postprandial plasma","volume":"413","author":"Nakajima","year":"2012","journal-title":"Clin Chim Acta"},{"key":"2022102613584224300_ehab551-B111","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0022-2275(20)37443-5","article-title":"Alterations of VLDL composition during alimentary lipemia","volume":"38","author":"Bj\u00f6rkegren","year":"1997","journal-title":"J Lipid Res"},{"key":"2022102613584224300_ehab551-B112","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.bbalip.2011.09.021","article-title":"Lipolysis of triglyceride-rich lipoproteins, vascular inflammation, and atherosclerosis","volume":"1821","author":"Schwartz","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"2022102613584224300_ehab551-B113","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s11883-009-0031-9","article-title":"Inflammation associated with the postprandial lipolysis of triglyceride rich lipoproteins by lipoprotein lipase","volume":"11","author":"Higgins","year":"2009","journal-title":"Curr Atheroscler Rep"},{"key":"2022102613584224300_ehab551-B114","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1161\/01.RES.0000258023.76515.a3","article-title":"Triglyceride-rich lipoproteins prime aortic endothelium for an enhanced inflammatory response to tumor necrosis factor-alpha","volume":"100","author":"Ting","year":"2007","journal-title":"Circ Res"},{"key":"2022102613584224300_ehab551-B115","doi-asserted-by":"crossref","first-page":"213S","DOI":"10.1093\/ajcn\/71.1.213S","article-title":"Fatty acid modulation of endothelial activation","volume":"71","author":"De Caterina","year":"2000","journal-title":"Am J Clin Nutr"},{"key":"2022102613584224300_ehab551-B116","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1194\/jlr.M700505-JLR200","article-title":"Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation","volume":"50","author":"Wang","year":"2009","journal-title":"J Lipid Res"},{"key":"2022102613584224300_ehab551-B117","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41590-019-0548-1","article-title":"Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation","volume":"21","author":"Zewinger","year":"2020","journal-title":"Nature Immunol"},{"key":"2022102613584224300_ehab551-B118","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1161\/01.CIR.102.6.670","article-title":"Remnant lipoproteins induce proatherothrombogenic molecules in endothelial cells through a redox-sensitive mechanism","volume":"102","author":"Doi","year":"2000","journal-title":"Circulation"},{"key":"2022102613584224300_ehab551-B119","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/jcp.41.9.940","article-title":"Association between coagulation factors VII and X with triglyceride rich lipoproteins","volume":"41","author":"de Sousa","year":"1988","journal-title":"J Clin Pathol"},{"key":"2022102613584224300_ehab551-B120","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0022-2275(20)32399-3","article-title":"Plasma and vessel wall lipoprotein lipase have different roles in atherosclerosis","volume":"41","author":"Clee","year":"2000","journal-title":"J Lipid Res"},{"key":"2022102613584224300_ehab551-B121","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/00041433-200012000-00008","article-title":"Remnant lipoproteins as therapeutic targets","volume":"11","author":"Havel","year":"2000","journal-title":"Curr Opin Lipidol"},{"key":"2022102613584224300_ehab551-B122","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/MOL.0000000000000330","article-title":"The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity","volume":"27","author":"Bor\u00e9n","year":"2016","journal-title":"Curr Opin Lipidol"},{"key":"2022102613584224300_ehab551-B123","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S0022-2275(20)38518-7","article-title":"Further resolution of the low density lipoprotein spectrum in normal human plasma: physicochemical characteristics of discrete subspecies separated by density gradient ultracentrifugation","volume":"29","author":"Chapman","year":"1988","journal-title":"J Lipid Res"},{"key":"2022102613584224300_ehab551-B124","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/MOL.0000000000000682","article-title":"Remnant lipoproteins: are they equal to or more atherogenic than LDL?","volume":"1","author":"Salinas","year":"2020","journal-title":"Curr Opin Lipidol"},{"key":"2022102613584224300_ehab551-B125","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1194\/jlr.M200322-JLR200","article-title":"ApoC-III content of apoB-containing lipoproteins is associated with binding to the vascular proteoglycan biglycan","volume":"43","author":"Olin-Lewis","year":"2002","journal-title":"J Lipid Res"},{"key":"2022102613584224300_ehab551-B126","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nature00804","article-title":"Subendothelial retention of atherogenic lipoproteins in early atherosclerosis","volume":"417","author":"Skalen","year":"2002","journal-title":"Nature"},{"key":"2022102613584224300_ehab551-B127","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1161\/01.ATV.15.4.534","article-title":"Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media","volume":"15","author":"Nordestgaard","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022102613584224300_ehab551-B128","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0021-9150(95)05770-6","article-title":"Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system","volume":"123","author":"Bjornheden","year":"1996","journal-title":"Atherosclerosis"},{"key":"2022102613584224300_ehab551-B129","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1161\/01.ATV.0000143859.75035.5a","article-title":"Arterial permeability and efflux of apolipoprotein B-containing lipoproteins assessed by in situ perfusion and three-dimensional quantitative confocal microscopy","volume":"24","author":"Proctor","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022102613584224300_ehab551-B130","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.ajpath.2017.09.019","article-title":"Extracellular lipids accumulate in human carotid arteries as distinct three-dimensional structures and have proinflammatory properties","volume":"188","author":"Lehti","year":"2018","journal-title":"Am J Pathol"},{"key":"2022102613584224300_ehab551-B131","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1161\/ATVBAHA.118.311269","article-title":"Macrophages shed excess cholesterol in unique extracellular structures containing cholesterol microdomains","volume":"38","author":"Jin","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022102613584224300_ehab551-B132","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1093\/eurheartj\/ehaa505","article-title":"Cholesterol crystals and atherosclerosis","volume":"41","author":"Baumer","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102613584224300_ehab551-B133","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0022-2275(20)40131-2","article-title":"Formation of cholesterol monohydrate crystals in macrophage-derived foam cells","volume":"35","author":"Tangirala","year":"1994","journal-title":"J Lipid Res"},{"key":"2022102613584224300_ehab551-B134","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/nature08938","article-title":"NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals","volume":"464","author":"Duewell","year":"2010","journal-title":"Nature"},{"key":"2022102613584224300_ehab551-B135","doi-asserted-by":"crossref","first-page":"e11765","DOI":"10.1371\/journal.pone.0011765","article-title":"Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation","volume":"5","author":"Rajam\u00e4ki","year":"2010","journal-title":"PLoS One"},{"key":"2022102613584224300_ehab551-B136","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0006-2952(03)00502-1","article-title":"Cholesterol crystallization and macrophage apoptosis: implication for atherosclerotic plaque instability and rupture","volume":"66","author":"Geng","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"2022102613584224300_ehab551-B137","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jacc.2014.11.039","article-title":"Cholesterol crystals associate with coronary plaque vulnerability in vivo","volume":"65","author":"Kataoka","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2022102613584224300_ehab551-B138","doi-asserted-by":"crossref","first-page":"104579","DOI":"10.1016\/j.jstrokecerebrovasdis.2019.104579","article-title":"Cholesterol crystals are associated with carotid plaque vulnerability: an optical coherence tomography study","volume":"29","author":"Shi","year":"2020","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"2022102613584224300_ehab551-B139","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1172\/JCI120123","article-title":"Alternative macrophages in atherosclerosis: not always protective!","volume":"128","author":"Pourcet","year":"2018","journal-title":"J Clin Invest"},{"key":"2022102613584224300_ehab551-B140","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1160\/TH16-08-0593","article-title":"Pathophysiological relevance of macrophage subsets in atherogenesis","volume":"117","author":"Liberale","year":"2017","journal-title":"Thromb Haemost"},{"key":"2022102613584224300_ehab551-B141","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1749-6632.1985.tb11860.x","article-title":"Lipoproteins of special significance in atherosclerosis. Insights provided by studies of type III hyperlipoproteinemia","volume":"454","author":"Mahley","year":"1985","journal-title":"Ann NY Acad Sci"},{"key":"2022102613584224300_ehab551-B142","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1161\/CIRCULATIONAHA.113.003008","article-title":"Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation","volume":"128","author":"Varbo","year":"2013","journal-title":"Circulation"},{"key":"2022102613584224300_ehab551-B143","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.atherosclerosis.2019.05.011","article-title":"A third of nonfasting plasma cholesterol is in remnant lipoproteins: lipoprotein subclass profiling in 9293 individuals","volume":"286","author":"Balling","year":"2019","journal-title":"Atherosclerosis"},{"key":"2022102613584224300_ehab551-B144","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1161\/01.ATV.20.1.189","article-title":"Action of atorvastatin in combined hyperlipidemia. Preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles","volume":"20","author":"Guerin","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022102613584224300_ehab551-B145","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0021-9150(02)00052-7","article-title":"Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates","volume":"164","author":"Forster","year":"2002","journal-title":"Atherosclerosis"},{"key":"2022102613584224300_ehab551-B146","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.atherosclerosis.2020.01.020","article-title":"Methodological issues regarding: \"A third of nonfasting plasma cholesterol is in remnant lipoproteins: lipoprotein subclass profiling in 9293 individuals\"","volume":"302","author":"Remaley","year":"2020","journal-title":"Atherosclerosis"},{"key":"2022102613584224300_ehab551-B147","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1515\/CCLM.2003.120","article-title":"Identification of lipoproteins of intestinal origin in human atherosclerotic plaque","volume":"41","author":"Pal","year":"2003","journal-title":"Clin Chem Lab Med"},{"key":"2022102613584224300_ehab551-B148","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1161\/01.ATV.14.11.1767","article-title":"Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque","volume":"14","author":"Rapp","year":"1994","journal-title":"Arterioscler Thromb"},{"key":"2022102613584224300_ehab551-B149","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1126\/science.106.2748.190","article-title":"Atherosclerosis and alimentary hyperlipemia","volume":"106","author":"Moreton","year":"1947","journal-title":"Science"},{"key":"2022102613584224300_ehab551-B150","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1161\/01.CIR.60.3.473","article-title":"Atherogenesis: a postprandial phenomenon","volume":"60","author":"Zilversmit","year":"1979","journal-title":"Circulation"},{"key":"2022102613584224300_ehab551-B151","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3389\/fcvm.2020.00010","article-title":"Monocytes and macrophages as protagonists in vascular complications of diabetes","volume":"7","author":"Kanter","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"2022102613584224300_ehab551-B152","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1161\/01.ATV.17.9.1707","article-title":"Uptake of type III hypertriglyceridemic VLDL by macrophages is enhanced by oxidation, especially after remnant formation","volume":"17","author":"Whitman","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022102613584224300_ehab551-B153","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"key":"2022102613584224300_ehab551-B154","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1001\/jamacardio.2020.0013","article-title":"A new equation for calculation of low-density lipoprotein cholesterol in patients with normolipidemia and\/or hypertriglyceridemia","volume":"5","author":"Sampson","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2022102613584224300_ehab551-B155","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1016\/j.jacc.2020.09.610","article-title":"VLDL cholesterol accounts for one-half of the risk of myocardial infarction associated with apoB-containing lipoproteins","volume":"76","author":"Balling","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2022102613584224300_ehab551-B156","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11886-020-01323-z","article-title":"Non-HDL cholesterol or apoB: which to prefer as a target for the prevention of atherosclerotic cardiovascular disease?","volume":"22","author":"Langlois","year":"2020","journal-title":"Curr Cardiol Rep"},{"key":"2022102613584224300_ehab551-B157","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2022102613584224300_ehab551-B158","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0009-8981(93)90062-9","article-title":"Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels","volume":"223","author":"Nakajima","year":"1993","journal-title":"Clin Chim Acta"},{"key":"2022102613584224300_ehab551-B159","doi-asserted-by":"crossref","first-page":"e002765","DOI":"10.1161\/JAHA.115.002765","article-title":"Remnant lipoprotein cholesterol and incident coronary heart disease: the Jackson Heart and Framingham Offspring Cohort Studies","volume":"5","author":"Joshi","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"2022102613584224300_ehab551-B160","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1194\/jlr.D800028-JLR200","article-title":"Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry","volume":"50","author":"Wiesner","year":"2009","journal-title":"J Lipid Res"},{"key":"2022102613584224300_ehab551-B161","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1093\/eurheartj\/ehw148","article-title":"Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol","volume":"37","author":"Laaksonen","year":"2016","journal-title":"Eur Heart J"},{"key":"2022102613584224300_ehab551-B162","doi-asserted-by":"crossref","first-page":"e121326","DOI":"10.1172\/jci.insight.121326","article-title":"Large-scale plasma lipidomic profiling identifies lipids that predict cardiovascular events in secondary prevention","volume":"3","author":"Mundra","year":"2018","journal-title":"JCI Insight"},{"key":"2022102613584224300_ehab551-B163","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1161\/01.ATV.5.2.162","article-title":"Fenofibrate reduces low density lipoprotein catabolism in hypertriglyceridemic subjects","volume":"5","author":"Shepherd","year":"1985","journal-title":"Arteriosclerosis"},{"key":"2022102613584224300_ehab551-B164","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/0002-9343(87)90873-4","article-title":"Changes in lipoprotein kinetics during therapy with fenofibrate and other fibric acid derivatives","volume":"83","author":"Ginsberg","year":"1987","journal-title":"Am J Med"},{"key":"2022102613584224300_ehab551-B165","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1161\/01.CIR.98.9.935","article-title":"Very low fat diets","volume":"98","author":"Lichtenstein","year":"1998","journal-title":"Circulation"},{"key":"2022102613584224300_ehab551-B166","doi-asserted-by":"crossref","first-page":"e673","DOI":"10.1161\/CIR.0000000000000709","article-title":"Omega-3 fatty acids for the management of hypertriglyceridemia: a Science Advisory from the American Heart Association","volume":"140","author":"Skulas-Ray","year":"2019","journal-title":"Circulation"},{"key":"2022102613584224300_ehab551-B167","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1136\/bmj.319.7224.1523","article-title":"Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors","volume":"319","author":"Rimm","year":"1999","journal-title":"BMJ"},{"key":"2022102613584224300_ehab551-B168","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000000510","article-title":"Dietary fats and cardiovascular disease: a presidential advisory from the American Heart Association","volume":"136","author":"Sacks","year":"2017","journal-title":"Circulation"},{"key":"2022102613584224300_ehab551-B169","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1146\/annurev.nu.15.070195.002353","article-title":"Trans fatty acids and their effects on lipoproteins in humans","volume":"15","author":"Katan","year":"1995","journal-title":"Annu Rev Nutr"},{"key":"2022102613584224300_ehab551-B170","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11883-019-0809-3","article-title":"Lomitapide and mipomersen-inhibiting Microsomal Triglyceride Transfer Protein (MTP) and apoB100 synthesis","volume":"21","author":"Blom","year":"2019","journal-title":"Curr Atheroscler Rep"},{"key":"2022102613584224300_ehab551-B171","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/14656566.2018.1550071","article-title":"Mipomersen and its use in familial hypercholesterolemia","volume":"20","author":"Parham","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"2022102613584224300_ehab551-B172","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11883-020-00858-4","article-title":"Lomitapide\u2014a microsomal triglyceride transfer protein inhibitor for homozygous familial hypercholesterolemia","volume":"22","author":"Stefanutti","year":"2020","journal-title":"Curr Atheroscler Rep"},{"key":"2022102613584224300_ehab551-B173","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart J"},{"key":"2022102613584224300_ehab551-B174","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.bbalip.2011.10.011","article-title":"Fish oil\u2014how does it reduce plasma triglycerides?","volume":"1821","author":"Shearer","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"2022102613584224300_ehab551-B175","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12944-017-0541-3","article-title":"Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review","volume":"16","author":"Oscarsson","year":"2017","journal-title":"Lipids Health Dis"},{"key":"2022102613584224300_ehab551-B176","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"2022102613584224300_ehab551-B177","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"key":"2022102613584224300_ehab551-B178","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1172\/JCI80025","article-title":"Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects","volume":"125","author":"Millar","year":"2015","journal-title":"J Clin Invest"},{"key":"2022102613584224300_ehab551-B179","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1194\/jlr.M018010","article-title":"Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib","volume":"53","author":"Krauss","year":"2012","journal-title":"J Lipid Res"},{"key":"2022102613584224300_ehab551-B180","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease","volume":"377","author":"Bowman","year":"2017","journal-title":"N Engl J Med"},{"key":"2022102613584224300_ehab551-B181","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","article-title":"Evacetrapib and cardiovascular outcomes in high-risk vascular disease","volume":"376","author":"Lincoff","year":"2017","journal-title":"N Engl J Med"},{"key":"2022102613584224300_ehab551-B182","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1006\/phrs.2001.0871","article-title":"PPARs, metabolic disease and atherosclerosis","volume":"44","author":"Fruchart","year":"2001","journal-title":"Pharmacol Res"},{"key":"2022102613584224300_ehab551-B183","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1161\/01.ATV.0000219283.10832.43","article-title":"Lipoprotein lipase S447X: a naturally occurring gain-of-function mutation","volume":"26","author":"Rip","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022102613584224300_ehab551-B184","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"2022102613584224300_ehab551-B185","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2337\/dc08-1543","article-title":"Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study","volume":"32","author":"Scott","year":"2009","journal-title":"Diabetes Care"},{"key":"2022102613584224300_ehab551-B186","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ahj.2018.09.011","article-title":"Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study","volume":"206","author":"Pradhan","year":"2018","journal-title":"Am Heart J"},{"key":"2022102613584224300_ehab551-B187","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1161\/ATVBAHA.118.311476","article-title":"Effects of APOC3 heterozygous deficiency on plasma lipid and lipoprotein metabolism","volume":"39","author":"Reyes-Soffer","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022102613584224300_ehab551-B188","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","article-title":"Targeting APOC3 in the familial chylomicronemia syndrome","volume":"371","author":"Gaudet","year":"2014","journal-title":"N Engl J Med"},{"key":"2022102613584224300_ehab551-B189","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N Engl J Med"},{"key":"2022102613584224300_ehab551-B190","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1161\/CIRCULATIONAHA.118.039107","article-title":"Inhibition of angiopoietin-like protein 3 with a monoclonal antibody reduces triglycerides in hypertriglyceridemia","volume":"140","author":"Ahmad","year":"2019","journal-title":"Circulation"},{"key":"2022102613584224300_ehab551-B191","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1093\/eurheartj\/ehaa689","article-title":"Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia","volume":"41","author":"Gaudet","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102613584224300_ehab551-B192","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/1865489","article-title":"Experimental therapeutics for challenging clinical care of a patient with an extremely rare homozygous APOC2 mutation","volume":"2020","author":"Ueda","year":"2020","journal-title":"Case Rep Endocrinol"},{"key":"2022102613584224300_ehab551-B193","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1161\/01.ATV.13.2.170","article-title":"Effects of simvastatin on apoB metabolism and LDL subfraction distribution","volume":"13","author":"Gaw","year":"1993","journal-title":"Arterioscler Thromb"},{"key":"2022102613584224300_ehab551-B194","doi-asserted-by":"crossref","first-page":"65B","DOI":"10.1016\/S0002-9149(98)00041-1","article-title":"Comparisons of statins in hypertriglyceridemia","volume":"81","author":"Stein","year":"1998","journal-title":"Am J Cardiol"},{"key":"2022102613584224300_ehab551-B195","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0026-0495(00)91169-7","article-title":"Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin","volume":"49","author":"Le","year":"2000","journal-title":"Metabolism"},{"key":"2022102613584224300_ehab551-B196","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.116.025253","article-title":"Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans","volume":"135","author":"Reyes-Soffer","year":"2017","journal-title":"Circulation"},{"key":"2022102613584224300_ehab551-B197","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1007\/s00125-019-4856-7","article-title":"Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study","volume":"62","author":"Rosenson","year":"2019","journal-title":"Diabetologia"},{"key":"2022102613584224300_ehab551-B198","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jacl.2019.12.003","article-title":"Impact of proprotein convertase subtilisin\/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects","volume":"14","author":"Taskinen","year":"2020","journal-title":"J Clin Lipidol"},{"key":"2022102613584224300_ehab551-B199","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1161\/ATVBAHA.120.315446","article-title":"Effects of evolocumab on the postprandial kinetics of apo (apolipoprotein) B100- and B48-containing lipoproteins in subjects with type 2 diabetes","volume":"41","author":"Taskinen","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022102613584224300_ehab551-B200","doi-asserted-by":"crossref","first-page":"14642","DOI":"10.1016\/S0021-9258(18)33329-5","article-title":"The effect of human C apolipoproteins on the in vitro hepatic metabolism of triglyceride emulsions in the rat","volume":"257","author":"Quarfordt","year":"1982","journal-title":"J Biol Chem"},{"key":"2022102613584224300_ehab551-B201","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1172\/JCI86610","article-title":"ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors","volume":"126","author":"Gordts","year":"2016","journal-title":"J Clin Invest"},{"key":"2022102613584224300_ehab551-B202","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1400283","article-title":"Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia","volume":"373","author":"Gaudet","year":"2015","journal-title":"N Engl J Med"},{"key":"2022102613584224300_ehab551-B203","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1161\/CIRCRESAHA.120.317128","article-title":"LDL-cholesterol reduction by ANGPTL3 inhibition in mice is dependent on endothelial lipase","volume":"127","author":"Wu","year":"2020","journal-title":"Circ Res"},{"key":"2022102613584224300_ehab551-B204","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"ELIPSE HoFH Investigators. Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"2022102613584224300_ehab551-B205","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1161\/ATVBAHA.120.315204","article-title":"ANGPTL3 inhibition with evinacumab results in faster clearance of IDL and LDL apoB in patients with homozygous familial hypercholesterolemia. Brief Report","volume":"41","author":"Reeskamp","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022102613584224300_ehab551-B206","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/42\/47\/4791\/46645089\/ehab551.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/42\/47\/4791\/46645089\/ehab551.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T11:22:19Z","timestamp":1666783339000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/42\/47\/4791\/6362485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,2]]},"references-count":206,"journal-issue":{"issue":"47","published-online":{"date-parts":[[2021,9,2]]},"published-print":{"date-parts":[[2021,12,14]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehab551","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,14]]},"published":{"date-parts":[[2021,9,2]]}}}